Alpha 2.0
Login Register
» Authors » Dolores Isla

Dolores Isla

Explore the profile of Dolores Isla including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 124
Citations 7404
Followers 0
Related Specialties
Oncology
Pulmonary Medicine
General Medicine
Top 10 Co-Authors
Pilar Garrido
Enriqueta Felip
Rafael Rosell
Manuel Cobo
Teresa Moran
Mariano Provencio
Bartomeu Massuti
Luis Paz-Ares
Margarita Majem
Javier de Castro
Published In
Clin Transl Oncol
Lung Cancer
Clin Lung Cancer
J Clin Oncol
Cancers (Basel)
Affiliations
Soon will be listed here.
Recent Articles
1.
First-line pembrolizumab in patients with advanced non-small cell lung cancer and high PD-L1 expression: real-world data from a Spanish multicenter study
Piedra A, Martinez-Recio S, Hernandez A, Moran T, Arriola E, Recuero-Borau J, et al.
Front Oncol . 2025 Jan; 14:1510278. PMID: 39741981
Introduction: Pembrolizumab stands as a first-line option for patients with advanced non-small cell lung cancer (NSCLC) and high programmed death-ligand 1 (PD-L1) expression (PD-L1 ≥50%). Several factors such as antibiotic...
2.
Sex differences in patients with Non-Small Cell Lung Cancer harboring driver fusions treated with tyrosine kinase inhibitors: a systematic review
Leporati R, Auclin E, Morchon D, Ferriol-Galmes M, Laguna J, Gorria T, et al.
Ther Adv Med Oncol . 2024 Dec; 16:17588359241306940. PMID: 39697619
Background: While targeted therapies have transformed the treatment landscape of oncogene-addicted non-small cell lung cancer (NSCLC), the influence of sex on treatment outcomes remains insufficiently understood. Objectives: This systematic review...
3.
Detection of genomic alterations in liquid biopsies from patients with non-small cell lung cancer using FoundationOne Liquid CDx: a cost-effectiveness analysis
Isla D, Alvarez R, Arnal M, Arriola E, Azkarate A, Azkona E, et al.
J Med Econ . 2024 Oct; 27(1):1379-1387. PMID: 39387325
Objective: Liquid biopsy (LB) is a non-invasive technique to detect genetic alterations by next-generation sequencing (NGS) when tissue biopsy is not available. This study aims to estimate in the Spanish...
4.
Peripheral Blood TCRβ Repertoire, IL15, IL2 and Soluble Ligands for NKG2D Activating Receptor Predict Efficacy of Immune Checkpoint Inhibitors in Lung Cancer
Sesma A, Pardo J, Isla D, M Galvez E, Gascon-Ruiz M, Martinez-Lostao L, et al.
Cancers (Basel) . 2024 Aug; 16(16). PMID: 39199571
The development of immune checkpoint inhibitors (ICIs) has changed the therapeutic paradigm of lung cancer (LC), becoming the standard of treatment for previously untreated advanced non-small cell lung cancer (NSCLC)...
5.
Expert Consensus on the Management of Adverse Events of Lorlatinib in the Treatment of ALK+ Advanced Non-small Cell Lung Cancer
Arriola E, de Castro J, Garcia-Campelo R, Bernardez B, Bernabe R, Bruna J, et al.
Clin Drug Investig . 2024 Jul; 44(8):553-576. PMID: 39085682
The use of anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitors (TKIs), such as lorlatinib, for the treatment of patients with ALK gene rearrangement (or ALK-positive) non-small cell lung cancer (NSCLC)...
6.
Impact of antibiotics, corticosteroids, and microbiota on immunotherapy efficacy in patients with non-small cell lung cancer
Zapata-Garcia M, Moratiel-Pellitero A, Isla D, Galvez E, Gascon-Ruiz M, Sesma A, et al.
Heliyon . 2024 Jul; 10(13):e33684. PMID: 39050456
Lung cancer is a leading cause of morbidity and mortality globally, with its high mortality rate attributed mainly to non-small cell lung cancer (NSCLC). Although immunotherapy with immune checkpoint inhibitors...
7.
Spatially Preserved Multi-Region Transcriptomic Subtyping and Biomarkers of Chemoimmunotherapy Outcome in Extensive-Stage Small Cell Lung Cancer
Peressini M, Garcia-Campelo R, Massuti B, Marti C, Cobo M, Gutierrez V, et al.
Clin Cancer Res . 2024 Apr; 30(14):3036-3049. PMID: 38630755
Purpose: Transcriptomic subtyping holds promise for personalized therapy in extensive-stage small cell lung cancer (ES-SCLC). In this study, we aimed to assess intratumoral transcriptomic subtype diversity and to identify biomarkers...
8.
Predictors of Immunotherapy Efficacy in Metastatic Non-Small Cell Lung Cancer: Lung Immune Prognostic Index and Immune-Related Toxicity
Moratiel Pellitero A, Zapata Garcia M, Gascon Ruiz M, Arbones-Mainar J, Lastra Del Prado R, Isla D
World J Oncol . 2024 Mar; 15(2):223-238. PMID: 38545481
Background: Immune checkpoint inhibitors (ICIs) have been proposed as the standard first-line and subsequent treatment for metastatic non-small cell lung cancer (NSCLC). This study analyzed whether patients with good lung...
9.
Biomarkers of Immunotherapy Response in Patients with Non-Small-Cell Lung Cancer: Microbiota Composition, Short-Chain Fatty Acids, and Intestinal Permeability
Moratiel-Pellitero A, Zapata-Garcia M, Gascon-Ruiz M, Sesma A, Quilez E, Ramirez-Labrada A, et al.
Cancers (Basel) . 2024 Mar; 16(6). PMID: 38539479
Immune checkpoint inhibitors have been proposed as the standard treatment for different stages of non-small-cell lung cancer in multiple indications. Not all patients benefit from these treatments, however, and certain...
10.
The S-REAL study: Spanish real-world data on unresectable stage III NSCLC patients treated with durvalumab after chemoradiotherapy
Gomez Rueda A, Taus A, Alvarez Alvarez R, Bernabe-Caro R, Chara L, Lopez-Brea M, et al.
Clin Transl Oncol . 2024 Mar; 26(7):1779-1789. PMID: 38512450
Objectives: The S-REAL study aimed to assess the effectiveness of durvalumab as consolidation therapy after definitive chemoradiotherapy (CRT) in a real-world cohort of patients with locally advanced, unresectable stage III...